Adoptive Autologous iNKT Cells(Beijing Gene Key Life Technology)

The goal of this clinical trial is to explore the efficacy and safety of autologous iNKT cells in patients with progressed hepatocellular carcinoma (HCC) after treatment with PD-1 antibody. The main question it aims to answer are:
* the efficacy of autologous iNKT cells in patients with progressed HCC after treatment with PD-1 antibody.
* the safety of autologous iNKT cells in patients with progressed HCC after treatment with PD-1 antibody.
Participants will be randomized 1:1 to receive Regorafenib + PD-1 + iNKT cells (RPI group) or the treatment of Regorafenib + PD-1 (RP group).
Researchers will compare RPI group and RP group to see whether the iNKT cells can achieve a better therapeutic effect on HCC patients with PD-1 resistance.